The number of people aged 65 and older living with Alzheimer’s disease in the US is expected to double by 2050. In the latest episode of TouchNEUROLOGY's "Visionary Voices" podcast, Dr Anthony Caggiano, Chief Medical Officer at Cognition Therapeutics, explores how biomarkers are transforming our understanding of Alzheimer’s disease, from diagnosis and disease progression to drug development and the future of clinical care. Check out the podcast, here:
https://touchneurology.com/podcast/how-are-biomarkers-shaping-alzheimers-disease-and-whats-next/
